miglustat has been researched along with Disease Exacerbation in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (28.57) | 29.6817 |
| 2010's | 14 (66.67) | 24.3611 |
| 2020's | 1 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Ardissone, A; Caciotti, A; Calamai, M; Casini, A; Deodato, F; Di Rocco, M; Fischetto, R; Fiumara, A; Guerrini, R; Mancardi, MM; Mangone, G; Marangi, A; Morrone, A; Parini, R; Pavone, FS; Procopio, E; Ricci, S; Salviati, A; Strisciuglio, P; Tonin, R | 1 |
| Barrio, SC; Extremera, VC; Gutiérrez-Solana, LG; Jiménez, IB; la Concepción Fournier Del Castillo, M; Marín, LL; Orduña, BE | 1 |
| Stellitano, LA; Verity, CM; Winstone, AM | 1 |
| Caciotti, A; Deodato, F; Dionisi-Vici, C; Donati, MA; Morrone, A; Procopio, E; Rampazzo, A; Scarpa, M; Taurisano, R | 1 |
| Adachi, K; Itamura, S; Jimbo, E; Miyauchi, A; Nakamura, S; Nakano, Y; Nanba, E; Narita, A; Osaka, H; Usui, M; Yamagata, T | 1 |
| Hawlitschka, A; Hovakimyan, M; Lukas, J; Maass, F; Petersen, J; Rolfs, A; Schmitt, O; Witt, M; Wree, A | 1 |
| Cornelisse, P; Mengel, E; Muller, A; Patterson, MC; Pineda, M; Schwierin, B; Vanier, MT | 1 |
| Abel, L; Bowman, EA; Desmond, P; Fahey, M; Velakoulis, D; Walterfang, M | 1 |
| Audoin, B; Burzykowski, T; Chabrol, B; Galanaud, D; Kaphan, E; Sedel, F; Tourbah, A; Tranchant, C; Vanier, MT | 1 |
| Ali, NF; Davidson, CD; Dobrenis, K; Micsenyi, MC; Ory, DS; Renault, S; Stephney, G; Vanier, MT; Walkley, SU | 1 |
| Dekomien, G; Lefeber, DJ; Morava, E; Wevers, RA; Willemsen, MA; Wortmann, SB | 1 |
| Berg, JE; Tallaksen, CM | 1 |
| Guitton, J; Masciullo, M; Modoni, A; Ricci, E; Santoro, M; Silvestri, G; Tonali, P | 1 |
| Fornfeist, S | 1 |
| Guthoff, R; Hovakimyan, M; Lukas, J; Maass, F; Petersen, J; Reichard, M; Rolfs, A; Stachs, O; Witt, M; Wree, A | 1 |
| Chien, YH; Huang, AC; Hwu, WL; Lee, NC; Peng, SF; Su, SC; Tsai, LK; Tseng, CC; Yang, CC | 1 |
| Klünemann, HH; Santosh, PJ; Sedel, F | 1 |
| Gordo, MM; Marfa, MP; Pérez-Poyato, MS | 1 |
| Guerrera, M; Ladisch, S | 1 |
| Alfonso, P; Capablo, JL; de Cabezón, AS; Franco, R; Giraldo, P; Pocovi, M | 1 |
| Froissart, R; Guffon, N; Maire, I | 1 |
2 review(s) available for miglustat and Disease Exacerbation
| Article | Year |
|---|---|
Treatable metabolic psychoses that go undetected: what Niemann-Pick type C can teach us.
Topics: 1-Deoxynojirimycin; Age of Onset; Ataxia; Diagnosis, Differential; Disease Progression; Enzyme Inhibitors; Genetic Testing; Humans; Magnetic Resonance Spectroscopy; Niemann-Pick Disease, Type C; Ophthalmoplegia; Prevalence; Psychotic Disorders; Splenomegaly; Treatment Outcome | 2012 |
[Current development and usefulness of biomarkers for Gaucher disease follow up].
Topics: 1-Deoxynojirimycin; Adult; Biomarkers; Chemokines, CC; Disease Progression; Enzyme Inhibitors; Female; Follow-Up Studies; Gaucher Disease; Glucosylceramidase; Glycoside Hydrolase Inhibitors; Hexosaminidases; Humans; Immunohistochemistry; Infant, Newborn; Peptidyl-Dipeptidase A; Pregnancy; Pregnancy Complications; Recombinant Proteins; Time Factors | 2007 |
19 other study(ies) available for miglustat and Disease Exacerbation
| Article | Year |
|---|---|
Pre-diagnosing and managing patients with GM1 gangliosidosis and related disorders by the evaluation of GM1 ganglioside content.
Topics: 1-Deoxynojirimycin; Biomarkers; Cells, Cultured; Disease Progression; Female; Fibroblasts; Flow Cytometry; G(M1) Ganglioside; Gangliosidosis, GM1; Glycoside Hydrolase Inhibitors; Humans; Lymphocytes; Male; Optical Imaging; Phenotype; Severity of Illness Index | 2019 |
Long-term normalization of cognitive and psychopathological alterations in a juvenile Niemann-Pick type C case.
Topics: 1-Deoxynojirimycin; Adolescent; Child; Cognition; Disease Progression; Early Diagnosis; Female; Glycoside Hydrolase Inhibitors; Humans; Longitudinal Studies; Niemann-Pick Disease, Type C | 2020 |
Niemann-Pick type C as a cause of progressive intellectual and neurological deterioration in childhood.
Topics: 1-Deoxynojirimycin; Adolescent; Adult; Age of Onset; Brain; Child; Child, Preschool; Delayed Diagnosis; Disease Progression; Epidemiological Monitoring; Female; Follow-Up Studies; Glycoside Hydrolase Inhibitors; Humans; Infant; Intellectual Disability; Male; Niemann-Pick Disease, Type C; Prospective Studies; Time Factors; United Kingdom | 2017 |
The treatment of juvenile/adult GM1-gangliosidosis with Miglustat may reverse disease progression.
Topics: 1-Deoxynojirimycin; Adult; Age Factors; beta-Galactosidase; Cognition Disorders; Disease Progression; Female; Follow-Up Studies; Gait; Gangliosidosis, GM1; Genotype; Glycoside Hydrolase Inhibitors; Humans; Language Disorders; Motor Skills; Movement Disorders; Neuropsychological Tests; Treatment Outcome; Walking; Young Adult | 2017 |
Miglustat therapy in a case of early-infantile Niemann-Pick type C.
Topics: 1-Deoxynojirimycin; Base Sequence; Carrier Proteins; Child, Preschool; Developmental Disabilities; Disease Progression; Glucosyltransferases; Humans; Intracellular Signaling Peptides and Proteins; Japan; Male; Membrane Glycoproteins; Mutation; Niemann-Pick C1 Protein; Niemann-Pick Disease, Type C | 2017 |
Reduced cerebellar neurodegeneration after combined therapy with cyclodextrin/allopregnanolone and miglustat in NPC1: a mouse model of Niemann-Pick type C1 disease.
Topics: 1-Deoxynojirimycin; Animals; Cell Count; Cerebellum; Cyclodextrins; Disease Models, Animal; Disease Progression; Drug Therapy, Combination; Enzyme Inhibitors; Mice; Nerve Degeneration; Neurons; Niemann-Pick Disease, Type C; Pregnanolone | 2015 |
Stable or improved neurological manifestations during miglustat therapy in patients from the international disease registry for Niemann-Pick disease type C: an observational cohort study.
Topics: 1-Deoxynojirimycin; Adolescent; Adult; Child; Child, Preschool; Cohort Studies; Disease Progression; Enzyme Inhibitors; Female; Humans; Male; Niemann-Pick Disease, Type C; Prospective Studies; Treatment Outcome; Young Adult | 2015 |
Longitudinal changes in cerebellar and subcortical volumes in adult-onset Niemann-Pick disease type C patients treated with miglustat.
Topics: 1-Deoxynojirimycin; Adolescent; Adult; Caudate Nucleus; Cerebellum; Disease Progression; Enzyme Inhibitors; Female; Humans; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Niemann-Pick Disease, Type C; Organ Size; Putamen; Thalamus; Young Adult | 2015 |
Normalisation of brain spectroscopy findings in Niemann-Pick disease type C patients treated with miglustat.
Topics: 1-Deoxynojirimycin; Adolescent; Adult; Aspartic Acid; Brain; Choline; Disability Evaluation; Disease Progression; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Linear Models; Longitudinal Studies; Male; Niemann-Pick Disease, Type C; Patient Dropouts; Treatment Outcome; Young Adult | 2016 |
Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression.
Topics: 1-Deoxynojirimycin; 2-Hydroxypropyl-beta-cyclodextrin; Animals; beta-Cyclodextrins; Cholesterol; Cyclodextrins; Disease Models, Animal; Disease Progression; Drug Synergism; Enzyme Inhibitors; Glycosphingolipids; Mice; Mice, Transgenic; Neurons; Niemann-Pick Disease, Type C; Pregnanolone; Treatment Outcome | 2009 |
Substrate deprivation therapy in juvenile Sandhoff disease.
Topics: 1-Deoxynojirimycin; Adolescent; Child, Preschool; Disease Progression; Enzyme Inhibitors; Glucosyltransferases; Hexosaminidase B; Humans; Male; Mutation; Sandhoff Disease | 2009 |
Miglustat therapy in juvenile Sandhoff disease.
Topics: 1-Deoxynojirimycin; Adolescent; beta-Hexosaminidase beta Chain; Cerebellum; Child, Preschool; Depression; Disease Progression; Electroconvulsive Therapy; Enzyme Inhibitors; Glucosyltransferases; Humans; Male; Mutation; Sandhoff Disease | 2009 |
Substrate reduction therapy with miglustat in chronic GM2 gangliosidosis type Sandhoff: results of a 3-year follow-up.
Topics: 1-Deoxynojirimycin; Disease Progression; Enzyme Inhibitors; Glucosyltransferases; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Muscle Weakness; Muscular Atrophy, Spinal; Neurologic Examination; Predictive Value of Tests; Sandhoff Disease; Time Factors; Treatment Outcome | 2010 |
[Niemann Pick type C disease].
Topics: 1-Deoxynojirimycin; Brain; Child; Child, Preschool; Chromosome Aberrations; Combined Modality Therapy; Developmental Disabilities; Diagnosis, Differential; Disability Evaluation; Disease Progression; Enzyme Inhibitors; Female; Genes, Recessive; Genetic Testing; Humans; Infant, Newborn; Magnetic Resonance Imaging; Niemann-Pick Disease, Type C; Parenting | 2010 |
Corneal alterations during combined therapy with cyclodextrin/allopregnanolone and miglustat in a knock-out mouse model of NPC1 disease.
Topics: 1-Deoxynojirimycin; Anesthetics; Animals; Chromatography, High Pressure Liquid; Chromatography, Liquid; Cornea; Cyclodextrins; Disease Progression; Drug Therapy, Combination; Enzyme Inhibitors; Genotype; Intracellular Signaling Peptides and Proteins; Lysosomes; Mass Spectrometry; Mice; Mice, Knockout; Microscopy, Confocal; Models, Biological; Mutation; Niemann-Pick C1 Protein; Niemann-Pick Disease, Type C; Pregnanolone; Proteins | 2011 |
Long-term efficacy of miglustat in paediatric patients with Niemann-Pick disease type C.
Topics: 1-Deoxynojirimycin; Child; Child, Preschool; Cognition; Deglutition; Disease Progression; Drug Administration Schedule; Female; Humans; Male; Nervous System Diseases; Niemann-Pick Disease, Type C; Time; Treatment Outcome | 2013 |
Initiation and discontinuation of substrate inhibitor treatment in patients with Niemann-Pick type C disease.
Topics: 1-Deoxynojirimycin; Adolescent; Carrier Proteins; Child; Child, Preschool; Developmental Disabilities; Disability Evaluation; Disease Progression; Enzyme Inhibitors; Female; Glucosyltransferases; Humans; Infant; Infant, Newborn; Intracellular Signaling Peptides and Proteins; Language Development Disorders; Male; Membrane Glycoproteins; Mutation; Niemann-Pick C1 Protein; Niemann-Pick Disease, Type C | 2012 |
N-butyldeoxynojirimycin inhibits murine melanoma cell ganglioside metabolism and delays tumor onset.
Topics: 1-Deoxynojirimycin; Animals; Cell Division; Cell Line, Tumor; Ceramides; Disease Progression; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gangliosides; Glucosyltransferases; Melanoma, Experimental; Mice; Neoplasm Transplantation | 2003 |
Neurologic improvement in a type 3 Gaucher disease patient treated with imiglucerase/miglustat combination.
Topics: 1-Deoxynojirimycin; Adult; Comorbidity; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Dystonia; Electroencephalography; Enzyme Inhibitors; Epilepsies, Myoclonic; Gaucher Disease; Glucosylceramidase; Humans; Male; Nervous System Diseases; Recombinant Proteins; Syndrome; Treatment Outcome | 2007 |